

|                          |  |
|--------------------------|--|
| <b>Product Name</b>      | : GS87   |
| <b>Synonyms</b>          | : 4-[5-[[[(3-Phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]]pyridine   |
| <b>Cat No.</b>           | : M22248   |
| <b>CAS Number</b>        | : 919936-70-2  |
| <b>Molecular Formula</b> | : C <sub>16</sub> H <sub>11</sub> N <sub>5</sub> O <sub>2</sub> S  |
| <b>Formula Weight</b>    | : 337.36   |
| <b>Chemical Name</b>     | : —  |
| <b>Description</b>       | : GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells. GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells |
| <b>Pathway</b>           | : PI3K/Akt/mTOR signaling  |
| <b>Target</b>            | : GSK-3  |
| <b>Receptor</b>          | : GSK-3  |
| <b>Solubility</b>        | : —  |
| <b>SMILES</b>            | : <chem>C([S]c1nnc(o1)c2ccncc2)c3nc(no3)c4ccccc4</chem>  |
| <b>Storage</b>           | : (-20°C)  |
| <b>Stability</b>         | : ≥ 2 years  |
| <b>Reference</b>         | :  |

1.Sophia, Hu, Masumi, et al. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.[J]. Molecular Cancer Therapeutics, 2016.